{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:48:28Z","timestamp":1793886508714,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clindermatol.2020.06.016","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T20:48:44Z","timestamp":1593463724000},"page":"607-612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Diagnosis and management of Stevens-Johnson syndrome\/toxic epidermal necrolysis"],"prefix":"10.1016","volume":"38","author":[{"given":"Megan H.","family":"Noe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2020.06.016_bb0005","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11593240-000000000-00000","article-title":"Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study","volume":"13","author":"Mittmann","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0015","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2133.2011.10705.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature","volume":"166","author":"Ziemer","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0020","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0030","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/FPC.0000000000000319","article-title":"Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Malaysian population","volume":"28","author":"Chong","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/dmpt-2016-0025","article-title":"An update on HLA alleles associated with adverse drug reactions","volume":"32","author":"Fricke-Galindo","year":"2017","journal-title":"Drug Metab Personalized Ther"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0045","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","article-title":"Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment","volume":"122","author":"Murata","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0050","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/ACI.0000000000000180","article-title":"Monitoring the acute response in severe hypersensitivity reactions to drugs","volume":"15","author":"Shiohara","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0055","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/toxins6010194","article-title":"Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions","volume":"6","author":"Su","year":"2014","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0060","doi-asserted-by":"crossref","first-page":"514","DOI":"10.7326\/0003-4819-151-7-200910060-00016","article-title":"Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome","volume":"151","author":"Abe","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0065","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0070","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0080","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.burns.2015.12.001","article-title":"Burn unit care of Stevens Johnson syndrome\/toxic epidermal necrolysis: a survey","volume":"42","author":"Le","year":"2016","journal-title":"Burns"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0085","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2016.06.035","article-title":"Bedside diagnostics in dermatology: parasitic and noninfectious diseases","volume":"77","author":"Micheletti","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/2042098611404094","article-title":"Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality","volume":"2","author":"Roujeau","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0095","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0105","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis-ABCD-10","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0110","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjd.14799","article-title":"Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"175","author":"Dodiuk-Gad","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0115","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0120","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A 10-year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J Burn Care Rehabil."},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0135","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.burns.2017.10.022","article-title":"Treatment of toxic epidermal necrolysis by a multidisciplinary team: a review of literature and treatment results","volume":"44","author":"Papp","year":"2018","journal-title":"Burns"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.survophthal.2016.01.004","article-title":"Stevens-Johnson syndrome: the role of an ophthalmologist","volume":"61","author":"Jain","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0145","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ophtha.2016.04.041","article-title":"New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome","volume":"123","author":"Gregory","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0150","first-page":"81","article-title":"Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"4","author":"Kaser","year":"2011","journal-title":"Rev Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0155","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cps.2017.02.016","article-title":"Burn center care of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"44","author":"Cartotto","year":"2017","journal-title":"Clin Plast Surg"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0160","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.amjsurg.2015.12.011","article-title":"Indications for intubation and early tracheostomy in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"211","author":"Williams","year":"2016","journal-title":"Am J Surg"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0165","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/BCR.0b013e3181cb8cb8","article-title":"What are the fluid requirements in toxic epidermal necrolysis?","volume":"31","author":"Shiga","year":"2010","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0170","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/0884533616642746","article-title":"Nutrition in toxic epidermal necrolysis: a multicenter review","volume":"31","author":"Graves","year":"2016","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0175","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.burns.2016.07.026","article-title":"Steven Johnson syndrome and toxic epidermal necrolysis in a burn unit: a 15-year experience","volume":"43","author":"McCullough","year":"2017","journal-title":"Burns"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0180","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/BCR.0000000000000208","article-title":"A 15-year review of pediatric toxic epidermal necrolysis","volume":"36","author":"Quirke","year":"2015","journal-title":"J Burn Care Res."},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures","volume":"89","author":"de Prost","year":"2010","journal-title":"Medicine"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0190","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.burns.2014.02.006","article-title":"A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres","volume":"40","author":"Mahar","year":"2014","journal-title":"Burns"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0195","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.burns.2007.06.008","article-title":"Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients","volume":"34","author":"Boorboor","year":"2008","journal-title":"Burns"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0200","first-page":"1026","article-title":"Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm","volume":"67","author":"Abela","year":"2014","journal-title":"JPRAS"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0205","first-page":"157","article-title":"Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"145","author":"Gueudry","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0210","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ophtha.2015.10.027","article-title":"Adjuvant role of amniotic membrane transplantation in acute ocular Stevens-Johnson syndrome: a randomized control trial","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0215","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/ICO.0b013e31823d02a8","article-title":"Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"31","author":"Hsu","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0220","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/j.jcjo.2018.08.020","article-title":"A modified technique for bedside amniotic membrane application to the eyelid margins for Stevens-Johnson syndrome","volume":"54","author":"Chen","year":"2019","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0225","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jtos.2019.03.001","article-title":"Sutureless amniotic membrane transplantation with cyanoacrylate glue for acute Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"17","author":"Shanbhag","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0230","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0029-7844(97)00596-6","article-title":"Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases","volume":"91","author":"Meneux","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0235","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0245","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2133.1976.tb00824.x","article-title":"Erythema multiforme in children: response to treatment with systemic corticosteroids","volume":"95","author":"Rasmussen","year":"1976","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0250","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0255","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0260","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clim.2009.09.006","article-title":"Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity","volume":"133","author":"Jacobi","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167120","article-title":"The effect of intravenous immunoglobulin combined with corticosteroid on the progression of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis","volume":"11","author":"Ye","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0270","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2015.08.033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis treatments: an Internet survey","volume":"74","author":"Curtis","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0275","first-page":"743","article-title":"High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases","volume":"20","author":"Chen","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0280","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-4632.2009.04166.x","article-title":"Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China","volume":"48","author":"Yang","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0285","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0290","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4103\/0378-6323.116738","article-title":"Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid","volume":"79","author":"Singh","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0295","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","article-title":"Cyclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174 patients-exposed\/unexposed and propensity score-matched analyses","volume":"138","author":"Poizeau","year":"2018","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0300","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","article-title":"Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches","volume":"137","author":"Gonz\u00e1lez-Herrada","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0305","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0310","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.jid.2018.03.1496","article-title":"Selective use of cyclosporine for Stevens-Johnson syndrome\/toxic epidermal necrolysis may exclude patients with poor prognostic factors","volume":"138","author":"Noe","year":"2018","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0315","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.4049\/jimmunol.159.11.5293","article-title":"Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense","volume":"159","author":"Berthou","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0320","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(05)74905-9","article-title":"Thalidomide in toxic epidermal necrolysis","volume":"353","author":"Klausner","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0325","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0330","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0335","first-page":"534","article-title":"Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab","volume":"85","author":"Al-Shouli","year":"2005","journal-title":"Acta Dermatovenereol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0340","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1345\/aph.1K001","article-title":"Etanercept for toxic epidermal necrolysis","volume":"41","author":"Famularo","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0345","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1346-8138.2009.00616.x","article-title":"Toxic epidermal necrolysis successfully treated with etanercept","volume":"36","author":"Gubinelli","year":"2009","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0350","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0355","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.016_bb0360","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20301498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20301498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:17:04Z","timestamp":1760033824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X20301498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0738081X20301498"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.06.016","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of Stevens-Johnson syndrome\/toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}